Archive

Filter

I am issuing a Buy recommendation on AMAG Pharmaceuticals (NSDQ: AMAG), a biotech company focusing on improving treatments for common but serious diseases such as complications of pregnancy and anemia. The stock is starting to show signs of accumulation and could deliver a significant intermediate term gain. Buy AMAG Pharmaceuticals up… Read More

Shares of Airgain (NSDQ: AIRG) hit their $16 sell stop last week and we are closing out this position. We held the stock for two months and took profits on one half of the position after the shares exploded up in response to a better than expected earnings report in November. Read More

We have more good news in this edition of Breakthrough Tech Weekly:Sell Airgain (NSDQ: AIRG) for a 37% gainSell Covisint (NSDQ: COVS) for a 9.9% gain.We’re also giving updates on  Bristol Myers Squib (NYSE: BMY),  Simulations Plus (NSDQ: SLP) and Argos Therapeutics (ARGS). Here are the details:Shares of Airgain (NSDQ:… Read More

I am recommending the purchase of Bristol-Myers Squibb Company (NYSE: BMY) up to $63, a leading global pharmaceutical company with a large oncology presence. The stock is starting to outperform the rest of the big pharma sector which suggests that there is a possible positive surprise in the offing, perhaps… Read More

When I added NVE Corp (NSDQ: NVEC) to the portfolio back on October 20th, I honestly couldn’t have timed it any better. But the share price and its valuation has run so far, so fast, I think our best bet is to take our gain and maybe come back to it later. Read More